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ell cycle exit is required for proper differentiation
in most cells and is critical for normal develop-
ment, tissue homeostasis, and tumor suppression.
However, the mechanisms that link cell cycle exit with dif-
ferentiation remain poorly understood. Here, we show
that the master melanocyte differentiation factor, mi-
crophthalmia transcription factor (MITF), regulates cell
cycle exit by activating the cell cycle inhibitor INK4A, a
tumor suppressor that frequently is mutated in melanomas.
MITF binds the INK4A promoter, activates p16
 
Ink4a
 
 mRNA
and protein expression, and induces retinoblastoma
C
 
protein hypophosphorylation, thereby triggering cell cycle
arrest. This activation of INK4A was required for efﬁcient
melanocyte differentiation. Interestingly, MITF was also
required for maintaining INK4A expression in mature
melanocytes, creating a selective pressure to escape
growth inhibition by inactivating INK4A. These ﬁndings
demonstrate that INK4A can be regulated by a differenti-
ation factor, establish a mechanistic link between melano-
cyte differentiation and cell cycle exit, and potentially
explain the tissue-speciﬁc tendency for INK4A mutations
to occur in melanoma.
 
Introduction
 
Terminal differentiation is accompanied by cell cycle exit in
most cell types, and this proclivity for mature cells to stop
dividing is important for normal development, tissue homeo-
stasis, and tumor suppression (Lipinski and Jacks, 1999). In
fact, the normal cellular function of many tumor suppressors is
to regulate differentiation and cell cycle exit (Lipinski and
Jacks, 1999). Nevertheless, the mechanisms that link differenti-
ation with cell cycle exit remain poorly understood.
Melanocytes are derived from neural crest and differenti-
ate under the control of microphthalmia transcription factor
(MITF), a basic helix-loop-helix leucine zipper transcription
factor that activates genes involved in pigment production
(e.g., DCT, TYR, and TRP1) and melanocyte survival (e.g.,
BCL2) (McGill et al., 2002; Bear et al., 2003; Widlund and
Fisher, 2003). Whether MITF also regulates cell cycle exit and
maintenance of the post-mitotic state in melanocytes is unclear.
We address that question here by investigating how MITF
affects the Rb-p16
 
Ink4a
 
 pathway, which plays a key role in cell
cycle exit and orderly progression through the differentiation
process in many cell types (Lipinski and Jacks, 1999).
 
Results and discussion
 
To examine the role of MITF in melanocyte cell cycle regula-
tion, we studied embryonic fibroblasts that differentiate into
melanocytes under the influence of ectopic MITF, as previ-
ously characterized (Tachibana et al., 1996; Bear et al., 2003).
Expression of MITF in 10T1/2 cells, which produce negligible
endogenous MITF protein (Fig. 1 A), resulted in marked
growth inhibition and morphologic changes consistent with
melanocyte differentiation (Fig. 1 B). BrdU incorporation
assays indicated that this growth block was due to cell cycle
arrest (Fig. 1 C). In contrast, no cell cycle alterations were
observed in cells expressing a MITF mutant lacking DNA-
binding activity (MITF-DB; Fig. 1 C), indicating that the ability
of MITF to negatively regulate the cell cycle is dependent on
its DNA-binding activity.
Consequently, we reasoned that the cell cycle inhibitory
activity of MITF might be mediated through interaction of the
MITF DNA-binding domain with cell cycle gene promoter ele-
ments. The canonical MITF recognition motif consists of a distal
M box containing a consensus CATGTG near the center and a
proximal E box (CANNTG) (Yasumoto et al., 1995). A search
of cell cycle regulatory gene promoters revealed multiple M
and E boxes in the promoter region of INK4A in both human
and mouse (Fig. 2 A). This finding was particularly interesting
because INK4A is a tumor suppressor that is frequently inacti-
vated in melanoma (Chin et al., 1998). Using chromatin im-
munoprecipitation assays, endogenous MITF from normal
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melanocytes was detected at the INK4A promoter in vivo (Fig.
2 B). Consistent with this finding, gel mobility shift assays
showed binding of endogenous MITF from Mel202 melanoma
cells to M and E box elements from the INK4A promoter in
vitro (Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200410115/DC1). Competition with either the unlabeled
M box or the unlabeled E box oligonucleotide inhibited bind-
ing of the other labeled oligonucleotides, suggesting that both
elements are required for maximal binding of MITF to the
INK4A promoter.
The ability of MITF to activate the INK4A promoter
was tested using an INK4A promoter driving a luciferase re-
porter in 10T1/2 cells. Expression of MITF in these cells
caused a dose-dependent increase in luciferase activity, with
up to 20-fold induction compared with cells transfected with
MITF-DB expression plasmid or a control empty vector (Fig.
2 C). In contrast, no induction was seen when two nucleotides
in the M box sequence were mutated, indicating that activa-
tion of the INK4A promoter by MITF requires the MITF-
binding motif. Consistent with these results, ectopic expres-
sion of MITF (but not MITF-DB) resulted in a substantial
increase in endogenous p16
 
Ink4a
 
 protein and mRNA levels in
10T1/2 cells (Fig. 1 A and Fig. 3 A).
Because p16
 
Ink4a
 
 induces a G1 cell cycle arrest by inhibit-
ing Cdk4 and allowing the accumulation of hypophosphory-
lated retinoblastoma protein (Rb) (Serrano et al., 1993), we ex-
amined the Rb protein in 10T1/2 cells after ectopic expression
Figure 1. MITF inhibits cell proliferation. (A) Western blot demonstrating
MITF, p16
Ink4a, total Rb, Rb-phospho-Ser780, and tubulin protein expression
in 10T1/2 mouse fibroblasts stably expressing ectopic MITF, MITF-DB
(DNA-binding mutant), or empty control vector. Arrows indicate hyper-
phosphorylated (top band) and hypophosphorylated (bottom band)
forms of Rb. (B) Growth curves of 10T1/2 cells stably expressing MITF
or empty control vector. Panels show morphology of 10T1/2 cells ex-
pressing control empty vector (left) and MITF (right). (C) BrdU incorpora-
tion assays in 10T1/2 cells expressing ectopic MITF , MITF-DB, or empty
control vector.
Figure 2. MITF activates the INK4A gene.
(A) The ARF/INK4A locus (also called
CDKN2A) and location of MITF-binding sites in
the INK4A promoter. Exons 1 , 1 , 2, and 3
are indicated, along with their contribution to
the INK4A and ARF mRNA transcripts. The
nucleotide positions, relative to the centromere,
are indicated. The INK4A promoter region is
located upstream of exon 1  and downstream
of exon 1 , which is transcribed only in the
p14ARF transcript. A distinct ARF promoter is
located upstream of exon 1 . Above the locus
map, the INK4A promoter is depicted in
greater detail for both human and mouse.
Each line represents 70 bases of FASTA se-
quence from the NCBI web site (http://
www.ncbi.nlm.nih.gov). Blue bars represent E
boxes and red bars M boxes. The E box and M
box nearest to the start site in exon 1  (green
lines) are indicated. The direction of transcrip-
tion is indicated by green arrows. (B) Chroma-
tin immunoprecipitation assay in normal mela-
nocytes. Chromatin was immunoprecipitated
with an anti-MITF antibody or control mouse
IgG, and then was PCR amplified using primers
for the INK4A promoter or the SILV gene pro-
moter, a known MITF target. (C) Luciferase as-
says in 10T1/2 cells transfected with expres-
sion vectors for MITF, MITF-DB, or an empty
vector control (EV), along with a luciferase re-
porter driven by the INK4A promoter or a mu-
tant INK4A promoter containing two nucleotide
substitutions in the M box (1x, 2x, and 3x  
1-, 2-, and 3- g plasmid DNA, respectively). 
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of MITF or MITF-DB. Neither MITF nor MITF-DB affected
total Rb protein levels in 10T1/2 cells, but only MITF induced
an accumulation of hypophosphorylated Rb (Fig. 1 A). In par-
ticular, MITF expression resulted in loss of phosphorylation at
Ser780, a CDK site that is preferentially phosphorylated by the
p16
 
Ink4a
 
 target Cdk4 and is known to be involved in regulation
of cell division and differentiation (Kitagawa et al., 1996; Bru-
garolas et al., 1999; Ma et al., 2003).
To investigate whether MITF is required to sustain en-
dogenous p16
 
Ink4a
 
 expression in melanocytic cells, we de-
pleted MITF in early passage normal melanocytes by RNA
interference. Compared with melanocytes transfected with
control scrambled small interfering RNA (siRNA) expression
vector, those transfected with MITF siRNA expression vector
exhibited markedly reduced levels of MITF and p16
 
Ink4a
 
mRNA and protein (Fig. 3, A and B). These changes were ac-
companied by an accumulation of hyperphosphorylated Rb
(Fig. 3 B). Consistent with these findings, depletion of MITF
caused melanocytes to reenter the cell cycle, as evidenced by
increased BrdU incorporation (Fig. 3 C), suggesting that the
MITF-p16
 
Ink4a
 
-Rb pathway is also important for maintenance
of the post-mitotic state in mature melanocytes. In contrast to
normal melanocytes, depletion of MITF in Mel202 melanoma
cells, which express low levels of p16
 
Ink4a
 
 (Fig. 3 D) as a re-
sult of promoter methylation (van der Velden et al., 2001),
had no effect on p16
 
Ink4a
 
 or Rb protein levels, Rb phosphoryla-
tion, or BrdU incorporation (Fig. 3, E and F). Thus, MITF in-
duces and maintains cell cycle exit in melanocytes, but this
regulatory mechanism can be disrupted in melanoma cells by
inactivation of INK4A.
Next, we established colonies of 10T1/2 cells stably ex-
pressing MITF and passaged them every 3 d, monitoring for
changes in growth rate. As described above, cells expressing
MITF initially exhibited a dramatically reduced growth rate.
However, after four or more passages occasional clones es-
caped the MITF-induced inhibition and began growing at a rate
comparable to parental cells that did not express MITF (Fig. 4 A).
In these escape clones, MITF mRNA and protein levels re-
mained unchanged, but p16
 
Ink4a
 
 mRNA and protein were mark-
edly reduced (Fig. 4, B and C). Further, methylation-specific
PCR assays revealed methylation of CpG islands (indicative of
gene inactivation) within the INK4A promoter in the escape
clones, but not in the growth-inhibited clones (Fig. 4 D). The
level of methylation was similar to that observed in Mel202
melanoma cells. Thus, inactivation of INK4A provides an es-
cape from MITF-induced growth inhibition, which may ex-
plain the strong selective pressure to silence INK4A during
melanoma formation (Chin et al., 1998).
Next, we examined whether melanocyte differentiation
and cell cycle arrest are independent processes. MITF and
Figure 3. MITF regulates p16
Ink4a and Rb in normal melanocytes, but not in melanoma cells. (A) Real-time PCR assays of MITF and INK4A mRNA levels in
10T1/2 cells expressing ectopic MITF or an empty control vector (left panels) and in UM41 normal melanocytes transfected with MITF siRNA or control
scrambled siRNA (right panels). Expression values represent fold difference compared with GAPDH. (B) Western blot analysis of MITF, p16
Ink4a, total Rb,
Rb-phospho-Ser780, and tubulin protein expression in UM41 cells 48 h after transfection with plasmids expressing MITF siRNA or control scrambled siRNA.
Arrows indicate hyperphosphorylated (top band) and hypophosphorylated (bottom band) forms of Rb. (C) BrdU incorporation assays in UM41 cells trans-
fected with MITF siRNA or control scrambled siRNA. (D) Real-time PCR assays of MITF and p16
Ink4a mRNA levels in untransfected Mel202 melanoma cells.
(E) Western blot analysis of MITF, p16
Ink4a, total Rb, Rb-phospho-Ser780, and tubulin protein expression in Mel202 cells 48 h after transfection with plasmids
expressing MITF siRNA or control scrambled siRNA. (F) BrdU incorporation assay in Mel202 cells expressing MITF siRNA or control scrambled siRNA. 
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MITF-DB were expressed in wild-type and INK4A-null pri-
mary mouse embryonic fibroblasts (MEFs), and then were
monitored for growth rate and morphology. As expected,
MITF (but not MITF-DB) inhibited the growth of wild-type
cells, but it had no growth inhibitory effect on INK4A-null
cells (Fig. 5 A). MITF efficiently blocked cell cycle progres-
sion in wild-type cells as measured by BrdU incorporation,
whereas no cell cycle inhibition was observed in INK4A-null
cells (Fig. 5 B). As with the 10T1/2 cells, MEFs expressing ec-
topic MITF exhibited morphologic changes consistent with
melanocyte differentiation (Fig. 5 C), but MITF did not induce
these changes in cells lacking INK4A (Fig. 5 C). Likewise, the
melanocyte differentiation marker S100 was detected in MITF-
expressing cells that were wild type for INK4A but not in those
that were null for INK4A (Fig. 5 D). Importantly, ectopic
MITF and MITF-DB levels were similar in wild-type and
INK4A-null MEFs (Fig. S2, available at http://www.jcb.org/
cgi/content/full/jcb.200410115/DC1). These results suggest
that MITF requires INK4A not only for cell cycle inhibition,
but also for efficient execution of the melanocyte differentia-
tion program. Indeed, Sviderskaya and coworkers found that
melanocytes lacking INK4A were more proliferative and less
differentiated than melanocytes having one or both copies of
INK4A (Sviderskaya et al., 2002).
These findings provide new mechanistic insights into
several biological problems. First, they provide an example of
how differentiation can be linked with cell cycle arrest. By
activating genes involved in cell cycle exit (i.e., INK4A) as
Figure 4. Cells that escape MITF-induced growth inhibition
exhibit silencing of INK4A. (A) Growth curve of 10T1/2 cells
stably expressing ectopic MITF. Growth-inhibited and escape
clones are indicated. (B) Real-time PCR measurement of MITF
and p16
Ink4a mRNA levels in a growth-inhibited clone and an
escape clone. Expression values are fold difference com-
pared with GAPDH. (C) Western blot analysis of MITF,
p16
Ink4a, and tubulin protein expression in a growth-inhibited
clone and an escape clone. (D) Methylation-specific PCR of
CpG island in the INK4A promoter region in a growth-inhibited
clone and an escape clone, as well as in Mel202 cells. “U”
indicates unmethylated and “M” indicates methylated primer
sets.
Figure 5 INK4A is required for MITF to execute the melanocyte
differentiation program. (A) Growth rate of INK4A-wildtype
and INK4A-null MEFs expressing ectopic MITF or MITF-DB.
(B) BrdU incorporation assays in INK4A-wildtype and
INK4A-null MEFs expressing ectopic MITF, MITF-DB, or
empty control vector. (C) Phase-contrast photomicrographs
(left panels) of INK4A-wildtype and INK4A-null MEFs expressing
ectopic MITF or MITF-DB. Only MITF-expressing wild-type
cells exhibit spindle morphology consistent with melanocyte
differentiation.  Immunofluorescence analysis (right panels)
of INK4A-wildtype and INK4A-null MEFs expressing ectopic
MITF. DAPI staining (blue) indicates cell nuclei, and green
staining indicates expression of the melanocyte marker S100. 
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well as melanocyte cell fate, MITF efficiently coregulates
these interrelated processes. Analogous to MITF, MyoD is a
helix-loop-helix transcription factor that induces both cell cy-
cle exit and differentiation in myoblasts (Sorrentino et al.,
1990). However, unlike our findings for MITF, MyoD-
induced cell cycle arrest does not appear to be a prerequisite
for myoblast differentiation. Second, our results show that
INK4A can be regulated directly by a differentiation factor.
This is a particularly relevant point because surprisingly little
is known about the transcriptional control of this important
cell cycle regulator. Third, our results provide new insights
into one of the most perplexing questions in cancer biology
(Sherr, 2004): why are specific tumor suppressors (many of
which are differentiation factors) associated with cancer in
certain cell types but not others? Our findings would suggest
that at least part of the answer lies in the mechanisms linking
differentiation and cell cycle exit in a given cell type. The di-
rect link between MITF and INK4A provides an attractive ex-
planation for the strong association between INK4A mutation
and melanoma (Ranade et al., 1995; Monzon et al., 1998).
Why do melanocytes mutate INK4A rather than MITF or Rb?
One potential explanation is that both MITF and Rb are re-
quired for melanocyte survival (Yavuzer et al., 1995; McGill
et al., 2002; Yu et al., 2003), whereas INK4A appears only to
regulate cell cycle.
A critical question that remains unanswered is how dif-
ferentiation is prohibited in the absence of cell cycle exit. One
speculation, based on the observation that E2F1 becomes
bound to hypophosphorylated Rb during differentiation (Ikeda
et al., 1996; Kastner et al., 1998), is that free E2F inhibits the
differentiation program. Rb-E2F may then serve as a check-
point to allow differentiation only when Rb is hypophosphory-
lated and able to induce G1 arrest. Further work is underway to
address this question.
 
Materials and methods
 
Cells and transfection
 
Mel202 human melanoma cells were a gift of B. Ksander (Harvard, Bos-
ton, MA). C3H 10T1/2 and primary MEFs were obtained from American
Type Culture Collection. Normal human melanocytes were described pre-
viously (Harbour et al., 2002). INK4A-null MEFs were generated at
E13.5 from FVB.129-CDKN2atm2.1Rdp mice (from Mouse Models of
Human Cancers Consortium, Frederick, MD). Cells were maintained in
DME with 10% FCS. MITF expression vector in pT7T3D-PacI was ob-
tained from American Type Culture Collection. MITF-DB was generated
by introducing a T-to-A nucleotide substitution in the MITF DNA-bind-
ing domain using site-directed mutagenesis with QuickChange II (Strat-
agene), resulting in an 
 
I
 
212
 
N
 
 substitution, which inhibits DNA binding
(Takebayashi et al., 1996). RNA interference was achieved using pSi-
lencer plasmid (Ambion) expressing MITF siRNA or scrambled control
siRNA (Xeragon). Luciferase assays were performed as described previ-
ously (Ma et al., 2003) using INK4A promoter-luciferase reporter (a gift
of G. Gores, Mayo Medical School, Rochester, MN) or a mutant pro-
moter generated by mutation of two nucleotides in the M box (CAACTG)
using site-directed mutagenesis. Constructs were verified by sequencing.
Transfections were performed with 1 
 
 
 
g test plasmid DNA (unless otherwise
indicated) using Effectene (QIAGEN).
 
BrdU and immunofluorescence assays
 
BrdU and immunofluorescence assays were performed as described previ-
ously (Ma et al., 2003). In brief, 10
 
5
 
 cells were transfected with the indi-
cated expression vectors, along with a GFP vector (10:1 ratio), on cover-
slips. For BrdU assays, cells were labeled with BrdU (1:1,000 dilution;
Amersham Biosciences) 24–72 h after transfection. After a further 12–36 h,
cells were rinsed with 1
 
 
 
 PBS, fixed in 3.7% formaldehyde for 15 min, per-
meabilized in 0.3% Triton X-100 for 15 min, and probed with an anti-BrdU
antibody (BD Biosciences) at 1:200 dilution in immunofluorescence buffer
for 1 h at 37
 
 
 
C in a humidified chamber. After washing the coverslips twice
with 1 ml/well PBS, the cells were incubated with Alexa Fluor–conjugated
secondary antibody (Molecular Probes, Inc.) at 1:1,000 dilution for 1 h.
Cells were stained with DAPI, mounted onto slides using Vectashield mount-
ing medium (Vector Laboratories) and analyzed by fluorescence micros-
copy. The percentage of cells incorporating BrdU was calculated from the
fraction of GFP-positive transfected cells that were positive for BrdU stain-
ing. For other immunofluorescence assays, cells were incubated with anti-
S100, anti-DCT, or anti-TRP1 primary antibodies and FITC- or Texas red–
conjugated secondary antibodies (all from Santa Cruz Biotechnology, Inc.)
and analyzed by fluorescence microscopy in a similar fashion.
 
Image acquisition
 
Microscopy was performed with an Olympus BX40 microscope (bright-
field) and an Olympus BH-2 microscope (fluorescence) using an Olympus
UPlanFL 40
 
 
 
 magnification objective lens with 0.75 aperture. Photomicro-
graphs were obtained at RT under air using the Olympus DP70 camera
(brightfield) and the Insight Spot RT camera (fluorescence). The fluoro-
chrome was Oregon green 488 (Molecular Probes, Inc.). Image acquisi-
tion was achieved with Olympus DP controller software. Minimal image
processing was performed with Adobe Photoshop.
 
Western blot
 
Western blots were performed as described previously (Ma et al., 2003)
using antibodies that recognize MITF (Oncogene Research Products), Rb
(sc102; Santa Cruz Biotechnology, Inc.), Rb-phospho-Ser780 (Cell Signal-
ing), p16
 
Ink4a
 
 (Cell Signaling), and gamma-tubulin (Sigma-Aldrich).
 
Quantitative PCR
 
Total RNA was collected using TRIzol (Invitrogen), cDNA was generated us-
ing Superscript First Strand Synthesis (Invitrogen), and amplification was per-
formed using the Platinum Quantitative PCR SuperMix-UDG kit (Invitrogen)
according to manufacturer’s instructions in an iCycler (Bio-Rad Laboratories).
LUX Fluorogenic primers for MITF-M and INK4A transcripts were: MITF-for-
ward 5
 
 
 
-CCGTTGGGCTTGCTGCATGT-3
 
 
 
, MITF-reverse 5
 
 
 
-CACCAACTAC-
CGTCTCTACTGGATGG-3
 
 
 
, INK4A forward 5
 
 
 
-CGGTCCCCTCCAGAG-
GATTTG-3
 
 
 
, INK4A-reverse 5
 
 
 
-CACCGCTCCTCTTTCTTCCTCCGG-3
 
 
 
.
 
Methylation-specific PCR
 
Genomic DNA was isolated using the DNeasy Tissue kit (QIAGEN), was
bisulfite modified, and was amplified with methylation-specific primers
for INK4A promoter CpG islands. Primer sequences are as follows:
methylated-forward 5
 
 
 
-TTTAAATACGTTTTTGTTGGTAGGC-3
 
 
 
, methyl-
ated-reverse 5
 
 
 
-ACGAATATAACACCCCTAAAATCG-3
 
 
 
, unmethylated-
forward 5
 
 
 
-TAAATATGTTTTTGTTGGTAGGTGG-3
 
 
 
, and unmethylated-
reverse 5
 
 
 
-CAAATATAACACCCCTAAAATCACC-3
 
 
 
. PCR was performed
using 0.5 
 
 
 
g template, 20 pmol each primer, 1.25 mM dNTP, 6.75 mM
MgCl
 
2
 
, 10
 
 
 
 PCR buffer (Invitrogen), and Taq Polymerase (Invitrogen).
Reactions were run at 94
 
 
 
C for 5 min, followed by 35 cycles of 94
 
 
 
C
(30 s), 53
 
 
 
C (30 s), and 72
 
 
 
C (30 s). PCR products were visualized on a
2.0% agarose gel containing ethidium bromide. Mel202 cells were used
as a positive control.
 
Chromatin immunoprecipitation assays
 
ChIP assays were performed using a commercial kit (Upstate Biotechnology)
as described by the manufacturer. In brief, 10
 
7
 
 normal melanocytes were
cross-linked in PBS containing proteinase inhibitors and 1% formaldehyde
for 15 min at 37
 
 
 
C, scraped and centrifuged (4 min, 2,000 rpm, 4
 
 
 
C), re-
suspended in SDS lysis buffer with proteinase inhibitors, sonicated, and
centrifuged (4 min, 2,000 rpm, RT). Dilution buffer was added, and super-
natants were precleared with 75 
 
 
 
l salmon sperm DNA/protein A. 1 
 
 
 
l
MITF antibody (Oncogene Research Products) or mouse IgG (negative
control) was added overnight at 4
 
 
 
C, then 60 
 
 
 
l salmon sperm DNA/pro-
tein A was added for 1 h at 4
 
 
 
C. The slurry was pelleted (1 min, 1,000
rpm, 4
 
 
 
C), and was washed 5 min each with low salt wash, high salt
wash, LiCl buffer, and TE buffer (10 mM Tris-HCl, pH 8.0, and 1 mM
EDTA). Samples were treated with 250 
 
 
 
l elution buffer (1% SDS/0.1M
NaHCO
 
3
 
) at RT for 15 min, then with 20 
 
 
 
l of 5M NaCl at 65
 
 
 
C for 4 h,
then with 0.5M EDTA/Tris-HCl and 2 
 
 
 
g proteinase K at 45
 
 
 
C for 1 h.
DNA was purified using the DNEasy kit (QIAGEN). PCR to detect the
INK4A and SILV promoters was performed with the following primers:
INK4A-5
 
 
 
-AGCATGTGCCTGTAATCCCAGCTA-3
 
 
 
, INK4A-5
 
 
 
-TGGGAGA- 
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CAAGAGCGAAACTTGGT-3
 
 
 
, SILV-5
 
 
 
-CATGGAGAACTTCCAAAAGG-
TGG-3
 
 
 
, and SILV-5
 
 
 
-TACTCTCCCCAGGGAGTATAAGT-3
 
 
 
.
 
Online supplemental material
 
Gel mobility shift assay demonstrates that MITF binds to the INK4A pro-
moter elements, and that efficient binding requires both the E box and the
M box (Fig. S1). Western blot analysis (Fig. S2 A) and immunofluores-
cence assays (Fig. S2 B) demonstrate that ectopic MITF is expressed at sim-
ilar levels in wild-type and INK4A-null MEFs. Online supplemental material
available at http://www.jcb.org/cgi/content/full/jcb.200410115/DC1.
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